Published in Proc Natl Acad Sci U S A on February 10, 2005
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Adv Anat Embryol Cell Biol (2012) 2.99
CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol (2010) 2.74
Skin β-endorphin mediates addiction to UV light. Cell (2014) 2.61
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol (2007) 2.01
Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A (2008) 1.97
Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 1.88
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol (2006) 1.77
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain (2011) 1.60
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
The endocannabinoid system and pain. CNS Neurol Disord Drug Targets (2009) 1.59
Peripheral mechanisms of pain and analgesia. Brain Res Rev (2008) 1.55
Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons. J Biol Chem (2006) 1.53
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
Neuroimmune interactions and pain: focus on glial-modulating targets. Curr Opin Investig Drugs (2008) 1.50
Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization. Eur J Neurosci (2010) 1.50
The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A (2006) 1.39
Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology (2008) 1.39
In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol (2006) 1.37
Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci (2008) 1.32
Peripherally acting mu-opioid receptor agonist attenuates neuropathic pain in rats after L5 spinal nerve injury. Pain (2008) 1.32
Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol (2006) 1.32
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev (2008) 1.28
Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci (2014) 1.25
Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol (2007) 1.24
Cutaneous sensory neurons expressing the Mrgprd receptor sense extracellular ATP and are putative nociceptors. J Neurophysiol (2008) 1.22
In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol (2007) 1.20
Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol (2011) 1.20
Nucleotide signaling and cutaneous mechanisms of pain transduction. Brain Res Rev (2008) 1.19
The analgesic potential of cannabinoids. J Opioid Manag (2010) 1.16
Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol (2011) 1.10
Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology (2007) 1.09
Peripheral delta opioid receptors require priming for functional competence in vivo. Eur J Pharmacol (2008) 1.07
Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One (2012) 1.05
2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective. J Med Chem (2014) 1.05
MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol (2008) 1.05
Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics (2006) 1.05
Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol (2006) 1.05
A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci (2010) 1.04
In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens. Planta Med (2008) 1.02
Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol (2009) 1.02
Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol (2008) 1.01
Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol Sci (2008) 1.01
Biologic mechanisms of oral cancer pain and implications for clinical therapy. J Dent Res (2011) 1.01
Mechanism of cancer pain. Mol Interv (2010) 1.00
The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology (2010) 0.99
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci (2009) 0.99
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov (2012) 0.99
Recombinant cannabinoid type 2 receptor in liposome model activates g protein in response to anionic lipid constituents. J Biol Chem (2011) 0.99
Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation. J Neurophysiol (2008) 0.98
Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol (2010) 0.98
Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res (2011) 0.97
Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci (2012) 0.96
Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett (2008) 0.96
New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol (2010) 0.95
Acute pharmacological modulation of mGluR8 reduces measures of anxiety. Behav Brain Res (2010) 0.95
The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br J Pharmacol (2008) 0.95
The emerging role of TRP channels in mechanisms of temperature and pain sensation. Curr Neuropharmacol (2006) 0.93
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav (2011) 0.93
Dynamic regulation of the endocannabinoid system: implications for analgesia. Mol Pain (2009) 0.93
CB2 Cannabinoid receptors as a therapeutic target-what does the future hold? Mol Pharmacol (2014) 0.93
The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res (2008) 0.92
Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor. Br J Pharmacol (2009) 0.92
The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis. Br J Pharmacol (2014) 0.92
Air-stimulated ATP release from keratinocytes occurs through connexin hemichannels. PLoS One (2013) 0.91
Cannabinoid CB2 receptors contribute to upregulation of β-endorphin in inflamed skin tissues by electroacupuncture. Mol Pain (2011) 0.91
Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. PLoS One (2010) 0.91
Mode of action of cannabinoids on nociceptive nerve endings. Exp Brain Res (2009) 0.90
Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control. Ther Clin Risk Manag (2005) 0.90
Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges. Behav Brain Res (2011) 0.89
Cannabinoids attenuate cancer pain and proliferation in a mouse model. Neurosci Lett (2010) 0.88
2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling. ChemMedChem (2009) 0.88
Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. Br J Pharmacol (2012) 0.88
"Sebocytes' makeup": novel mechanisms and concepts in the physiology of the human sebaceous glands. Pflugers Arch (2011) 0.87
Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. AAPS J (2010) 0.87
Modulating the delicate glial-neuronal interactions in neuropathic pain: promises and potential caveats. Neurosci Biobehav Rev (2014) 0.86
Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg (2010) 0.86
Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor. J Biol Chem (2012) 0.85
Demethylating drugs as novel analgesics for cancer pain. Clin Cancer Res (2014) 0.84
Significance of cannabinoid CB1 receptors in improgan antinociception. J Pain (2007) 0.84
Desensitization of transient receptor potential ankyrin 1 (TRPA1) by the TRP vanilloid 1-selective cannabinoid arachidonoyl-2 chloroethanolamine. Mol Pharmacol (2011) 0.83
Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. Mol Pain (2011) 0.83
CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav Pharmacol (2011) 0.82
Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons. Neuropharmacology (2011) 0.82
Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. Br J Pharmacol (2013) 0.82
Peripheral interactions between cannabinoid and opioid systems contribute to the antinociceptive effect of crotalphine. Br J Pharmacol (2014) 0.82
TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation. ACS Chem Neurosci (2014) 0.82
The neurobiology of cancer pain. Neuroscientist (2014) 0.81
The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J (2013) 0.81
Contributions of academic laboratories to the discovery and development of chemical biology tools. J Med Chem (2013) 0.81
Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms. Brain Res (2008) 0.81
Skin Matters: A Review of Topical Treatments for Chronic Pain. Part One: Skin Physiology and Delivery Systems. Pain Ther (2015) 0.81
PnPP-19, a spider toxin peptide, induces peripheral antinociception through opioid and cannabinoid receptors and inhibition of neutral endopeptidase. Br J Pharmacol (2016) 0.80
Salvinorin A reduces mechanical allodynia and spinal neuronal hyperexcitability induced by peripheral formalin injection. Mol Pain (2012) 0.80
Pro-inflammatory obesity in aged cannabinoid-2 receptor-deficient mice. Int J Obes (Lond) (2015) 0.79
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology (2017) 0.78
Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist. Life Sci (2012) 0.78
β-caryophyllene and β-caryophyllene oxide-natural compounds of anticancer and analgesic properties. Cancer Med (2016) 0.78
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain (1988) 18.17
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A (1999) 5.11
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A (1997) 3.26
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol (2000) 2.83
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A (1995) 2.33
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci U S A (1990) 1.79
Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol (1997) 1.71
Regulation of human epidermal melanocyte biology by beta-endorphin. J Invest Dermatol (2003) 1.66
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest (2003) 1.61
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 1.60
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain (2002) 1.55
Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med (2003) 1.54
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.42
Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. J Clin Invest (1997) 1.27
AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Eur J Pharmacol (1997) 1.25
Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology (2001) 1.21
The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett (1995) 1.20
Epidermal differentiation and basement membrane formation by HaCaT cells in surface transplants. Eur J Cell Biol (1998) 1.20
The Meissner corpuscle revised: a multiafferented mechanoreceptor with nociceptor immunochemical properties. J Neurosci (2001) 1.16
Coupling of the expressed cannabinoid CB1 and CB2 receptors to phospholipase C and G protein-coupled inwardly rectifying K+ channels. Receptors Channels (1999) 1.02
Proopiomelanocortin gene product regulation in keratinocytes. J Invest Dermatol (1996) 0.97
Matrix metalloproteinase-1 activates a pertussis toxin-sensitive signaling pathway that stimulates the release of matrix metalloproteinase-9. J Neurochem (2002) 0.92
Gi-mediated activation of mitogen-activated protein kinase (MAPK) pathway by receptor mimetic basic secretagogues of connective tissue-type mast cells: bifurcation of arachidonic acid-induced release upstream of MAPK. J Pharmacol Exp Ther (1999) 0.89
Characterization of solubilized human and rat brain beta-endorphin-receptor complex. Proc Natl Acad Sci U S A (1986) 0.84
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Topographically distinct epidermal nociceptive circuits revealed by axonal tracers targeted to Mrgprd. Neuron (2005) 3.54
Pathologic alterations of cutaneous innervation and vasculature in affected limbs from patients with complex regional pain syndrome. Pain (2006) 3.20
Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain (2008) 2.91
Unmasking the tonic-aversive state in neuropathic pain. Nat Neurosci (2009) 2.77
Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice. Neuron (2010) 2.69
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain (2005) 2.27
Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain (2002) 2.24
Dynorphin A activates bradykinin receptors to maintain neuropathic pain. Nat Neurosci (2006) 2.23
A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther (2004) 2.21
Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem (2004) 2.17
Central modulation of pain. J Clin Invest (2010) 2.12
Multiple actions of systemic artemin in experimental neuropathy. Nat Med (2003) 2.12
AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther (2004) 2.08
TRPA1 modulates mechanotransduction in cutaneous sensory neurons. J Neurosci (2009) 2.07
Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J Neurosci (2002) 2.00
Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. Anesthesiology (2007) 1.96
ASIC3, an acid-sensing ion channel, is expressed in metaboreceptive sensory neurons. Mol Pain (2005) 1.95
Antinociceptive and nociceptive actions of opioids. J Neurobiol (2004) 1.93
Voltage-gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol (2004) 1.93
Redistribution of Na(V)1.8 in uninjured axons enables neuropathic pain. J Neurosci (2003) 1.89
Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain (2007) 1.88
Molecular identification of rapidly adapting mechanoreceptors and their developmental dependence on ret signaling. Neuron (2009) 1.88
Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers (2005) 1.83
Engagement of descending inhibition from the rostral ventromedial medulla protects against chronic neuropathic pain. Pain (2011) 1.82
Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals (2005) 1.80
Molecular genetic visualization of a rare subset of unmyelinated sensory neurons that may detect gentle touch. Nat Neurosci (2007) 1.78
The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain (2011) 1.70
Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. Am J Hum Genet (2004) 1.70
Similarities and differences in the innervation of mystacial vibrissal follicle-sinus complexes in the rat and cat: a confocal microscopic study. J Comp Neurol (2002) 1.68
Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. Anesthesiology (2002) 1.63
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain (2011) 1.60
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 1.60
The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain (2006) 1.59
Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci (2002) 1.58
Reversal of pancreatitis-induced pain by an orally available, small molecule interleukin-6 receptor antagonist. Pain (2010) 1.58
Peripheral mechanisms of pain and analgesia. Brain Res Rev (2008) 1.55
Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med (2003) 1.54
Parallel synthesis and biological evaluation of different sizes of bicyclo[2,3]-Leu-enkephalin analogues. Biopolymers (2005) 1.54
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53
Spinal L-type calcium channel blockade abolishes opioid-induced sensory hypersensitivity and antinociceptive tolerance. Anesth Analg (2005) 1.53
An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain (2005) 1.49
Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain (2005) 1.49
Medullary pain facilitating neurons mediate allodynia in headache-related pain. Ann Neurol (2009) 1.48
CB2 cannabinoid receptor mediation of antinociception. Pain (2006) 1.47
Persistent restoration of sensory function by immediate or delayed systemic artemin after dorsal root injury. Nat Neurosci (2008) 1.47
Natural history of herpes zoster: late follow-up of 3.9 years (n=43) and 7.7 years (n=10). Pain (2013) 1.46